Home
Search
Study Topics
Glossary
|
Study 8 of 2651 for search of: | United States, Connecticut |
Previous Study | Return to Search Results | Next Study |
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00067938 |
Bipolar study of tolerability, clinical response and patient satisfaction
Condition | Intervention | Phase |
---|---|---|
Bipolar Disorder |
Drug: lamotrigine |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | An Open-Label Study of Tolerability, Clinical Response, and Satisfaction in Adult Bipolar I Subjects Optimizing Initiation of Therapy Using Administration of Dermatological Precautions and LAMICTAL Titration Packs |
Estimated Enrollment: | 1200 |
Study Start Date: | August 2003 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Chair: | GSK Clinical Trial, MD | GlaxoSmithKline |
Study ID Numbers: | SCA40917 |
Study First Received: | September 3, 2003 |
Last Updated: | June 25, 2007 |
ClinicalTrials.gov Identifier: | NCT00067938 |
Health Authority: | United States: Food and Drug Administration |
bipolar disorder lamotrigine |
Calcium, Dietary Affective Disorders, Psychotic Mental Disorders Bipolar Disorder |
Lamotrigine Mood Disorders Psychotic Disorders |
Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Therapeutic Uses Calcium Channel Blockers |
Cardiovascular Agents Central Nervous System Agents Anticonvulsants Pharmacologic Actions |